Medicenna Therapeutics Quote - MDNA

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

1.34

Bid

1.33

Offer

1.42

Volume

120,844

1.32 Day's Range 1.39

0.64 52 Week Range 2.98

Market Cap

93.314M

Previous Close

1.32

Open

1.39

Last Trade

4100

1.34

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

69,296

Shares Outstanding

69,637,000

Dividend Yield

PE Ratio

-3.64

Earnings Per Share (EPS)

-0.37

Revenue

Net Profit

-25.47M

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.medicenna.com

Headquarters

Toronto, Ontario, Can

Founded

Medicenna Therapeutics Corp is listed in the Biological Pds,ex Diagnstics sector of the Toronto Stock Exchange with ticker MDNA. The last closing price for Medicenna Therapeutics was $1.32. Over the last year, Medicenna Therapeutics shares have traded in a share price range of $ 0.64 to $ 2.98.

Medicenna Therapeutics currently has 69,637,000 shares in issue. The market capitalisation of Medicenna Therapeutics is $91.92 million. Medicenna Therapeutics has a price to earnings ratio (PE ratio) of -3.64.

Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones

- Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck’s (known as MSD...

Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025

TORONTO and HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or...

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and...

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when...

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

TORONTO and HOUSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or...

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

MDNA11 shows significant survival benefits in preclinical glioblastoma models, expanding CD8+ T and NK cells...

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR...

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

TORONTO and HOUSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or...

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort...

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.08	6.34920634921	1.26	1.46	1.19	125655	1.28605225	CS
4	-0.02	-1.47058823529	1.36	1.53	1.17	65682	1.30761682	CS
12	-0.19	-12.4183006536	1.53	2.14	1.17	69296	1.53527474	CS
26	-0.83	-38.2488479263	2.17	2.62	1.17	72621	1.84222898	CS
52	0.64	91.4285714286	0.7	2.98	0.64	107211	1.88222089	CS
156	-0.8	-37.3831775701	2.14	2.98	0.215	65285	1.42540645	CS
260	-2.21	-62.2535211268	3.55	7.25	0.215	71530	2.69990236	CS

MDNA - Frequently Asked Questions (FAQ)

What is the current Medicenna Therapeutics share price?

The current share price of Medicenna Therapeutics is $ 1.34

How many Medicenna Therapeutics shares are in issue?

Medicenna Therapeutics has 69,637,000 shares in issue

What is the market cap of Medicenna Therapeutics?

The market capitalisation of Medicenna Therapeutics is CAD 91.92M

What is the 1 year trading range for Medicenna Therapeutics share price?

Medicenna Therapeutics has traded in the range of $ 0.64 to $ 2.98 during the past year

What is the PE ratio of Medicenna Therapeutics?

The price to earnings ratio of Medicenna Therapeutics is -3.64

What is the reporting currency for Medicenna Therapeutics?

Medicenna Therapeutics reports financial results in CAD

What is the latest annual profit for Medicenna Therapeutics?

The latest annual profit of Medicenna Therapeutics is CAD -25.47M

What is the registered address of Medicenna Therapeutics?

The registered address for Medicenna Therapeutics is 200 - 1920 YONGE STREET, TORONTO, ONTARIO, M4S 3E2

What is the Medicenna Therapeutics website address?

The website address for Medicenna Therapeutics is www.medicenna.com

Which industry sector does Medicenna Therapeutics operate in?

Medicenna Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
TCTucows Inc	$ 27.11 (26.50%)	43.57k
RTGRTG Mining Inc	$ 0.025 (25.00%)	18.01k
VRTSVertiqal Studios Corporation	$ 0.025 (25.00%)	1.28M
EXNExcellon Resources Inc	$ 0.13 (23.81%)	1.29M
XAMXanadu Mines Ltd	$ 0.055 (22.22%)	79.28k
BABYElse Nutrition Holdings Inc	$ 0.015 (-25.00%)	318.5k
PPTAPerpetua Resources Corp	$ 13.15 (-22.51%)	451.6k
LCFSTidewater Renewables Ltd	$ 0.61 (-19.74%)	77.67k
CNTCentury Global Commodities Corporation	$ 0.025 (-16.67%)	77k
SEASeabridge Gold Inc	$ 15.98 (-15.63%)	51.93k
ACAir Canada	$ 17.74 (-2.63%)	7.16M
SUSuncor Energy Inc	$ 56.05 (-1.11%)	6.72M
MFCManulife Financial Corporation	$ 42.07 (0.05%)	6.5M
TRPTC Energy Corporation	$ 65.13 (-3.08%)	5.96M
TDToronto Dominion Bank	$ 84.62 (-0.55%)	4.89M

Seminole Red 5 minutes ago

YUK

Seminole Red 8 minutes ago

nice win, Big points

robinandthe7hoods 8 minutes ago

Even way back in the Wayfinder days of 2023,the Verses technology,now called Genius was built to fit on top of existing systems,both software and hardware,integrate and enhance the system already in place to maximize the capabilities for each company.
Genius is not made to replace,but to

VRSSF

fuagf 25 minutes ago

Remind us how much Trump cares for the Bill of Rights, or any other part of the Constitution. Or the other jerk...

https://www.usnews.com/object/image/00000195-0583-d285-a7bf-7f9fb4c30000/20250212edohc-a.jpg?update-time=1739554653232&size=responsiveGallery

eagle8 37 minutes ago

autologous assassin 🇺🇸 🇺🇦 🇮🇱
@flaskworks
Roswell Park Cancer Institute, a world-renowned leader in immunotherapy research, wouldn’t have signed over their 27-year dendritic cell IP portfolio to $NWBO unless they had full confidence in the

NWBO

fuagf 39 minutes ago

Holy catfish. Thanks. ;-)

igotthemojo 40 minutes ago

they built facilities and never said where, except to say it was in Vietnam...they could have built it in Quang Nam on the property they are already leasing...but why would they build a facilty there if they already had a facility there?...

LAREC and the VSA may have provided a locati

KBLB

fuagf 42 minutes ago

Teachable. Ask which is heavier, dry or humid air .. stop! .. don't read any more until you answer

https://www.washingtonpost.com/news/capital-weather-g

fuagf 50 minutes ago

Maybe he'll have visited by the time he gets back.

Dragonman1 51 minutes ago

Just Waiting for the Quarterly Report and if it's what I expect it should be epic, who doesn't like beer and also where the super bashers are then you should know that is a good sign, they want it to fail but that won't happen,
IMHO this Co is gonna take off sooner or later, remember bashers

KEGS

TightCoil 1 hour ago

Ask: Does HawkEye Buffett know something
about Fannie and Freddie that we don't know.
And is he preparing to do something shocking?

FNMA

oldstocks 1 hour ago

Proof OneMind Technologies is part of the Spain 2025 push Digital Transformation as in part of the Kit Consulting

This is huge for OneMind Technologies and it is only starting to sink into our minds here, after OneMindNG post on LinkedIn 2 weeks ago!

I knew i stumbled

AFFU

demonsmith 2 hours ago

One day closer to trading

TWOH

Budman33 2 hours ago

Not to late to buy. Anyone have a shiny crystal 🔮 for Fridays close. IMO higher than where we are. Stock acting beautiful.

VDRM

fuagf 2 hours ago

LOL Haven't seen any sign he would appreciate anything.

Anyway, only notice, B4 out for two, usher for three. Weeks this time.

Life will be easier.

lodas 2 hours ago

I am becoming more and more skeptical as we head into uncharted waters with this new administration....Perception is everything on wall street, so here is a couple of game changers to think about.... (1) Warren Buffet has been quietly liquidating stocks in his portfolio.... (2) Deep Seek has thrown

NVDA

Alexulf 2 hours ago

Oh dear :-) who and what are you? LOL :-) you are stuck in a self-destructive behavior.
Chill, just chill. This rambling on of yours eats you up, not healthy at all, seriously!

AITX

janice shell 2 hours ago

LOLOLOL!!

Alexulf 2 hours ago

AITX’s Fastest Sale Ever + RADCam’s Next Move – Steve’s Big Update!

https://radsecurity.us18.list-manage.com/trac...7eae867c17

AITX

oldstocks 2 hours ago

OneMindNG driving digital transformation

We were delighted to have been a part of the Orange Business MEA Sales Kick-off 2025 and have the opportunity to showcase our #SmartCity and #loT solutions.
Affluence Corporation

Thierry Scozzesi • 3rd+
Chie

AFFU

fuagf 2 hours ago

Felt tired, sheeted it, slept about 3.5h?? guess was tired of suggesting

https://substackcdn.com/image/fetch/w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F3d1c6491-71ec-463c-be9e-f2dc0b7b58f6_1125x841.jpeg

gp22 2 hours ago

$TSSI: $DELL & Elon X-Ai $5B server contract likely drives $TSSI significantly higher this week. Time to load up. Only 13M free Float. Nuts.
https://www.kxan.com/elon-musk/dell-secures-deal-worth-more-than-5b-in-elon-musks-xai-startup-company/

DELL TSSI

fuagf 2 hours ago

Felt tired, sheeted it, slept about 3.5h?? guess was tired os suggesting

https://substackcdn.com/image/fetch/w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F3d1c6491-71ec-463c-be9e-f2dc0b7b58f6_1125x841.jpeg

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Medicenna Therapeutics Corp (MDNA) Share Price

Medicenna Therapeutics Corp (MDNA)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

About Medicenna Therapeutics Corp

Ask ADVFN Intelligence (AI)

MDNA Latest News

Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones

Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones

Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

MDNA - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free